Rivaroxaban

Generic Name: Rivaroxaban

Brand Names: Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₈ClN_₃O_₅S

CAS Number: 366789-02-8

Unique Ingredient Identifier: 9NDF7JZ4M3

Background: Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...

Indication: Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...

Associated Conditions: Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism

Associated Therapies: -

Clinical Trials

Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients

Conditions: Pulmonary Embolism

First Posted Date: 2020-08-26

Last Posted Date: 2020-08-26

Lead Sponsor: China-Japan Friendship Hospital

Target Recruit Count: 496

Registration Number: NCT04527042

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Phase 3

Terminated

Conditions: Coronavirus Disease 2019 (COVID-19)

Interventions: Other: Placebo
Drug: Rivaroxaban
Other: Standard of Care (SOC)

First Posted Date: 2020-08-11

Last Posted Date: 2023-07-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1284

Registration Number: NCT04508023

Locations: 🇺🇸
Morehouse School of Medicine, Atlanta, Georgia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Franciscan Research Center, Tacoma, Washington, United States

and more 14 locations

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Rivaroxaban

First Posted Date: 2020-08-07

Last Posted Date: 2021-10-22

Lead Sponsor: Bill & Melinda Gates Medical Research Institute

Target Recruit Count: 497

Registration Number: NCT04504032

Locations: 🇺🇸
Woodland Research Northwest LLC - ERG - PPDS, Rogers, Arkansas, United States
🇺🇸
Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States
🇺🇸
Encompass Care, North Las Vegas, Nevada, United States

and more 17 locations

Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Other: Standard Of Care (SOC)
Drug: Rivaroxaban

First Posted Date: 2020-06-04

Last Posted Date: 2022-01-12

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 111

Registration Number: NCT04416048

Locations: 🇩🇪
Katholisches Klinikum Koblenz-Montabaur (Catholic Hospital Koblenz-Montabaur), Koblenz, Rheinland-Pfalz, Germany
🇩🇪
Kardiologie und Angiologie I Universitätsherzzentrum Freiburg, Freiburg, Baden-Württemberg, Germany
🇩🇪
Immanuel Klinikum Bernau Herzzentrum Brandenburg ( Immanuel Clinic Bernau Heart Center Brandenburg), Bernau, Brandenburg, Germany

and more 21 locations

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

Phase 2

Conditions: COVID-19

Interventions: Drug: Chloroquine or Hydroxychloroquine
Drug: Lopinavir/Ritonavir
Other: Best standard of care
Drug: Asunercept 100mg
Drug: Asunercept 400mg
Drug: non-RAS blocking antihypertensives
Drug: Asunercept 25mg
Drug: Remdesivir
Drug: Thromboprophylaxis
Drug: Rivaroxaban
Drug: Candesartan
Drug: Pentaglobin

First Posted Date: 2020-04-17

Last Posted Date: 2021-03-02

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 500

Registration Number: NCT04351724

Locations: 🇦🇹
Medical University of Innsbruck, Innsbruck, Tirol, Austria
🇦🇹
Wilhelminenspital, Vienna, Austria
🇦🇹
SMZ Ost Donauspital, Vienna, Austria

and more 6 locations

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial

Phase 3

Completed

Conditions: Severe Acute Respiratory Syndrome
Coronavirus

Interventions: Drug: Aspirin
Drug: Rivaroxaban
Drug: Interferon-Beta
Drug: Colchicine

First Posted Date: 2020-03-27

Last Posted Date: 2024-01-11

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 6667

Registration Number: NCT04324463

Locations: 🇨🇦
Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada
🇧🇷
Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil
🇨🇦
London Health Sciences Centre, London, Ontario, Canada

and more 63 locations

Italian Registry In the Setting of AF Ablation With Rivaroxaban (IRIS)

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban
Procedure: Catheter ablation

First Posted Date: 2020-03-20

Last Posted Date: 2020-06-05

Lead Sponsor: Dr Carlo Lavalle

Target Recruit Count: 250

Registration Number: NCT04315974

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico Umberto I - Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche., Roma, Italy

Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Phase 3

Conditions: Rivaroxaban
Thromboprophylaxis
Cancer

Interventions: Drug: Rivaroxaban

First Posted Date: 2020-03-16

Last Posted Date: 2020-03-16

Lead Sponsor: LiuZhou People's Hospital

Target Recruit Count: 204

Registration Number: NCT04309240

Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD

Not yet recruiting

Conditions: Peripheral Arterial Disease

Interventions: Drug: Aspirin
Drug: Rivaroxaban

First Posted Date: 2020-03-12

Last Posted Date: 2021-03-10

Lead Sponsor: Poznan University of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT04305028

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Active, not recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Apixaban
Drug: Edoxaban
Drug: Rivaroxaban
Drug: Dabigatran

First Posted Date: 2020-03-05

Last Posted Date: 2023-06-06

Lead Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Target Recruit Count: 700

Registration Number: NCT04297150

Locations: 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
🇪🇸
Hospital Gómez Ulla, Madrid, Spain
🇪🇸
Hospital Universitario de La Paz, Madrid, Spain

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy